FibroBiologics, Inc. Common Stock
FBLG
Rank in Stocks
#29962
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm,... FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Share Price
$0.9577
Last synced: 2026-11-09
Market Cap
$6.38M
Change (1 day)
-2.24%
Change (1 year)
-85.81%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade FibroBiologics, Inc. Common Stock (FBLG)
Category
Healthcare
EPS for FibroBiologics, Inc. Common Stock (FBLG)
EPS as of June 2026 TTM: $-6.00
According to FibroBiologics, Inc. Common Stock's latest financial reports, its current EPS (TTM) is $-6.00. At the end of 2025 the company had an EPS of $-8.35, a decrease compared to its 2024 EPS of $-6.80.
EPS history for FibroBiologics, Inc. Common Stock from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-6.00 | -28.14% |
| 2025 | $-8.35 | 22.79% |
| 2024 | $-6.80 | -42.37% |
| 2023 | $-11.80 | 268.75% |
| 2022 | $-3.20 | 228.54% |
| 2021 | $-0.97 | 35.28% |
| 2020 | $-0.72 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -361.00% |
US
|
|
| $-7.07 | 17.83% |
US
|
|
| $-5.29 | -11.83% |
AU
|
|
| $12.88 | -314.67% |
BE
|
|
| $21.56 | -459.33% |
NL
|
Questions about FibroBiologics, Inc. Common Stock's earnings per share (EPS)
What is FibroBiologics, Inc. Common Stock's earnings per share (EPS)?
FibroBiologics, Inc. Common Stock's earnings per share (EPS) over the last twelve months is $-6.00, as of Jun 2026.
What was FibroBiologics, Inc. Common Stock's earnings per share (EPS) in 2025?
In 2025, FibroBiologics, Inc. Common Stock's earnings per share (EPS) was $-8.35, compared with $-6.80 in 2024.
How has FibroBiologics, Inc. Common Stock's earnings per share (EPS) changed since 2020?
From 2020 to 2025, FibroBiologics, Inc. Common Stock's earnings per share (EPS) was highest in 2020 ($-0.72) and lowest in 2023 ($-11.80).
How does FibroBiologics, Inc. Common Stock's earnings per share (EPS) compare with similar companies?
FibroBiologics, Inc. Common Stock's earnings per share (EPS) ($-6.00) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.